Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0225 • ACR Convergence 2020
Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study
Hawazin Alhazzani¹, Reem Tashkandi¹, Lamia Alzamel¹, Haya Almalag¹, Shiekha Alaujan¹, Abdurhman Alarfaj¹, Hussain Alarfaj¹ and Mohammed Omair¹, ¹King Saud University, Riyadh, Saudi Arabia
Background/Purpose: Biologics have been advocated by guidelines as effective therapies for rheumatoid arthritis (RA)1. Limited longitudinal studies investigated the prevalence and risk factors for developing…
Abstract Number: 0241 • ACR Convergence 2020
A Prospective Analysis of Factors Impacting Medication Adverse Events in Patients with Rheumatoid Arthritis
Elizabeth Salt¹, Amanda Wiggins¹ and Mary Kay Rayens¹, ¹University of Kentucky, Lexington, KY
Background/Purpose: Rheumatoid arthritis (RA), a chronic autoimmune disease affecting approximately 1.5 million people in the U.S., is characterized by inflammation of the synovial tissues with…
Abstract Number: 0485 • ACR Convergence 2020
Non-obese Rheumatoid Arthritis Patients with Low Low-density Lipoprotein Have Higher Coronary Atherosclerosis Burden, Greater Plaque Progression and Cardiovascular Event Risk
George Karpouzas¹, Sarah Ormseth¹, Elizabeth Hernandez¹ and Matthew Budoff¹, ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA
Background/Purpose: RA patients with low body weight incur higher mortality than obese patients. Paradoxically, RA patients in the lowest low-density lipoprotein group (LDL < 70…
Abstract Number: 0585 • ACR Convergence 2020
Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
Jan Sorensen¹, Mette Aadahl², Merete Hetland³, Bente Appel Esbensen⁴ and Tanja Thomsen², ¹Healthcare Outcomes Research Centre, Dublin, Dublin, Ireland, ²Centre for Clinical Research and Prevention, Frederiksberg, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark, ⁴University of Copenhagen, Glostrup, Hovedstaden, Denmark
Background/Purpose: The “Joint Resources – Sedentary Behaviour” randomised controlled trial (RCT) (1,2,3) aimed to reduce sedentary behaviour in patients with rheumatoid arthritis (RA) by means…
Abstract Number: 0750 • ACR Convergence 2020
Nuclei Detection in Rheumatoid Arthritis Synovial Tissue Using Artificial Intelligence
Steven Guan¹, David Slater¹, James Thompson¹, Edward DiCarlo², Diyu Pearce-Fisher², Susan Goodman³, Bella Mehta⁴ and Dana Orange⁵, ¹MITRE, McLean, VA, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Rockefeller University, New York
Background/Purpose: Hematoxylin and eosin (H&E) stained rheumatoid arthritis synovium are routinely used to assess inflammation [1]. In this work, we propose an automated approach using…
Abstract Number: 0767 • ACR Convergence 2020
Anti-acetylated Protein Antibodies in Rheumatoid Arthritis (RA): Clues for the Starting Point of Autoantibody Responses in RA
Tineke van Wesemael¹, Nazike Salioska², Annemarie Dorjée¹, Thomas Huizinga¹, Annette van der Helm - van Mil³, René Toes¹ and Diane van der Woude¹, ¹Leiden university medical center, Leiden, Netherlands, ²leiden university medical center, Rotterdam, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies such as rheumatoid factor (RF) and anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-carbamylated…
Abstract Number: 0784 • ACR Convergence 2020
Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis
Jimeng Xue¹, Liling Xu¹, Fanlei Hu¹ and Yin Su², ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic)
Background/Purpose: The study aimed to investigate the expression and clinical significance of Tyro3TK on CD14+CD16+ and CD14+CD16- monocyte subsets and explore the effect of Tyro3TK…
Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Xue Han², Joe Zhuo², Amy Schrader¹, Nicole Middaugh¹, Page Moore¹ and Vadim Khaychuk², ¹Corrona, LLC, Waltham, MA, ²Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…
Abstract Number: 0817 • ACR Convergence 2020
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Geoffrey Littlejohn¹, Tegan Smith², Kathleen Tymms³, Peter Youssef⁴, Helen Cooley⁵, Sabina Ciciriello⁶, David Mathers⁷, Catherine OSullivan² and Hedley Griffiths⁸, ¹Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁴University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia, ⁵Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁶Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ⁷Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁸Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia
Background/Purpose: JAK inhibitors (JAKi) are targeted synthetic DMARDs (tsDMARDs) with a different mode of action (MOA) to conventional synthetic and biologic DMARDs (cs and bDMARDs).…
Abstract Number: 0834 • ACR Convergence 2020
Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Stefano Fiore¹, Lang Chen², Cassie Clinton², Huifeng Yun², Amy Praestgaard³, Kerri Ford³ and Jeffrey R Curtis², ¹Sanofi, Bridgewater, NJ, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Sanofi, Cambridge, MA
Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
Abstract Number: 0999 • ACR Convergence 2020
CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells
Claire Rempenault¹, Julie Mielle², Kristina Schreiber¹, Pierre Corbeau³, Jacques Morel⁴, Claire Daien⁴ and Rachel Audo², ¹Rheumatology, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³immunology, Nimes, France, ⁴Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: Human regulatory B cells still need to be characterized. Given the absence of phenotypical definition, a functional definition based on their ability to secrete…
Abstract Number: 1015 • ACR Convergence 2020
The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
Chou Luan Tan¹, Boon Han Ng², Noor Shahrazat Ahmad², Shahrul Aiman Soelar², Muhammad Zulhilmi Asyraf Jazlan², Mohd Ammar Dzakirin Md Mansor², Mohd Azri Mohd Suan², Kuang Kiat Kiew², Zalwani Zainuddin², Muhammad Radzi Abu Hassan² and Chong Hong Lim², ¹Hospital Sultanah Bahiyah, Kementerian Kesihatan Malaysia, Alor Setar, Kedah, Malaysia, ²Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia
Background/Purpose: Majority of DMARDs, including methotrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, the clinical findings were inconsistent.…
Abstract Number: 1186 • ACR Convergence 2020
Red Cell Distribution Width and Absolute Lymphocyte Count Associate with Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis
Sofi Damjanovska¹, Lenche Kostadinova², Ibtissam Gad³, Sameena Syed⁴, Alyssa Lange⁵, Corinne Kowal⁶, Carey Shive⁷, Christopher Burant⁸, Brigid Wilson⁹, Taissa Bej⁹, Nora Singer¹⁰, David Canaday⁴, Maya Mattar¹¹, David Zidar⁴ and Donald Anthony¹², ¹Case Western Reserve University/Cleveland VA Medical Center, Cleveland Heights, OH, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ³Case Western Reserve/ Cleveland VA Medical Center, Cleveland Heights, OH, ⁴Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁵Cleveland VA Medical Center, Cleveland, ⁶Case western reserve university/Cleveland VA Medical Center, ohio, ⁷(2) Department of Pathology, Case Western Reserve University, ohio, ⁸Case Western Reserve University, Cleveland, ⁹Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ¹⁰The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ¹¹Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ¹²Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Peripheral blood red cell distribution width (RDW) and absolute lymphocyte count (ALC) are associated with aging, cardiovascular disease (CVD), and mortality in the general…
Abstract Number: 1202 • ACR Convergence 2020
Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis
Manon Guillouard¹, Nicolas Authier¹, Bruno Pereira¹, Martin Soubrier¹ and Sylvain Mathieu¹, ¹CHU Gabriel Montpied, Clermont-Ferrand, France
Background/Purpose: Despite classic analgesic or effective treatments in rheumatic diseases, such as synthetic Disease Modifying Anti-Rheumatic Drugs in rheumatoid arthritis (RA), patients remain in pain…
Abstract Number: 1218 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Alan Kivitz¹, Yoshiya Tanaka², Susan Lee³, Lei Ye³, Hao Hu³, Robin Besuyen⁴ and Bernard Combe⁵, ¹Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵University of Montpellier, Montpellier, France
Background/Purpose: In the FINCH 1 study, filgotinib (FIL)—an oral, potent, selective JAK1 inhibitor—plus methotrexate (MTX) provided significant improvements in signs and symptoms of rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].